Producing proteins is a time-consuming, painstaking process, particularly from mammalian cell lines, and the investment required in terms of time, expertise, cost and infrastructure prevents most researchers from taking on the task in their own laboratories. Obtaining proteins from commercial sources is prohibitively expensive for scientists on tight budgets.
“Having this service close at hand has been fantastic for my research,” says EPFL researcher Patrick Fraering. “In my field [neurodegenerative disease] developments move very quickly. In order to stay competitive internationally, I need quick access to proteins from mammalian cell lines, and there is no way I could produce them with this level of efficiency myself.”
Building on the demonstrated benefits of the facility to EPFL researchers, the School of Life Sciences decided to formalize the facility and extend the service to scientists doing basic research outside EPFL. This will allow the Facility to recoup some costs and has the added benefit of stimulating collaborations and cross-institutional exchange. It’s cost-effective for users, because even though they will be charged a fee for the proteins, it’s far below what they would pay for commercial proteins and roughly a quarter of what it would cost them to produce the proteins themselves. And with a tight turnaround time – the facility can produce proteins from mammalian cells in less than four weeks – researchers can quickly follow up on promising leads. Once the development of a protein reaches a clinical or commercial stage, production will be transferred to a commercial facility.
The facility also provides training in gene transfer techniques and cultivation of cells in suspension. As facility manager David Hacker points out, “by offering guidance and training, we can enhance the chance that researchers’ projects will succeed.”
Recombinant proteins - From a Swiss past to a Swiss future?
In 1978, Swiss scientist Werner Arber shared the Nobel prize in medicine with Americans Daniel Nathans and Hamilton Smith for discovering a technique to incorporate non-native DNA into living cells. The re-combined, or “recombinant”, DNA holds instructions for the cell to produce the non-native protein which can subsequently be extracted and purified.
The 25,000 genes that make up human genome hold the blueprints for the manufacture of anywhere from 250,000 - 1 million proteins. But only about 50 of these proteins are understood well enough to be used in therapeutic applications. Insulin, EPO, and herceptin, an antibody used in breast cancer treatment, are a few better-known examples.
The global market for antibodies, proteins, and hormones produced using the recombinant DNA technique is currently on the order of $20 billion. Global demand for insulin is expected to rise by 14% annually. Most biomedical researchers agree that the therapeutic and market potential of recombinant proteins is not even close to being fully exploited. “It’s very important that we take advantage of the opportunities available in recombinant proteins,” notes Wurm. “A lack of opportunity for exploring this potential will diminish the European contribution to biomedical research considerably, and we’re likely to get left behind in the market as well.”
“If we want to jump-start biomedical research on proteins in Europe, the path from idea to innovation needs to be optimized,” urges Wurm. “With this facility, EPFL is in a key position to help make this happen.”
Mary Parlange | alfa
Discovery of a Key Regulatory Gene in Cardiac Valve Formation
24.05.2017 | Universität Basel
Carcinogenic soot particles from GDI engines
24.05.2017 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...
In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.
In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
24.05.2017 | Physics and Astronomy
24.05.2017 | Physics and Astronomy
24.05.2017 | Event News